With Arvinas’ first patient dosed in February 2024, targeting the CNS with protein degradation technology just got hotter. Neurodegeneration is a shiny object for drug developers and with plenty of chemistry, target selection, PKPD and distribution challenges still to overcome, not to mention the blood brain barrier (BBB), coupled with the momentum of new companies flocking to the field, 2025 is going to be a thrilling year for neurodegenerative protein degradation.
The 2nd Protein Degradation for CNS Summit will unite 60+ Neuroscience, Biology, Chemistry, DMPK, Toxicology from early discovery to early clinical research as they:
- Delve into the translational processes required to advance protein degradation drugs for CNS diseases to clinic as preclinical success brings more biotech and pharma companies closer than ever, making this focus imperative. Hear from industry leading experts, including Arvinas, AUTOTAC Bio and Sanofi on bridging this gap and progressing through trials
- Explore the latest results from studies investigating the mechanisms for successful protein degradation within the brain, be informed on the most recent findings to aid drug discovery for neurodegenerative disease with Biogen and Captor Therapeutics
- Gain insight into the most cutting edge approaches of designing protein degraders from development of libraries and high-throughput screening techniques to AI modelling of degrader molecules with UbiquiTX
- Understand the current methodologies for solving the unique pharmacokinetic challenges within the brain and how to optimise drug development for these consideration with Harvard University
- Examine the advancements in techniques, strategies and approaches from a range of companies and research groups including Sybilla and Draupnir Bio Aps as they lead case studies and share results from newly published papers on protein degradation for neurodegenerative disease
Don't miss your only chance to hear from 20+ neuroscience and protein degradation experts as the CNS disease targets for novel protein degraders gain momentum in 2025.
Why Attend the Workshop Day?
Gain knowledge into CNS and BBB biology to unlock a deeper understanding for aiding advancements, with Marianthi Papakosta, Director of Neuroscience Biology Research, Neurocrine Biosciences
Explore approaches for tackling neurodegenerative disease to assess drug impacts for better future development, with Ram Krishnan, Head of Neurodegenerative Disease Cluster, Sanofi
Examine strategies of successful protein degradation for better understanding and future progression, Mikolaj Slabicki, Faculty Member, Massachusetts General Hospital
Explore protein degradrer biology to enhance insights for greated context and collaboration, with Pranam Chatterjee, Co-Founder of UbiquitX, Assistant Professor, Duke University
Who Will You Meet?
40+ neuroscientists, structural and chemical biologists, medicinal chemists, pharmacologists and protein degrader experts from the leading biotechnology and pharmaceutical companies in the industry.
What Your Peers Have to Say
“Very dense program, great lineup of speakers, focused discussions.”
Monte Rosa Therapeutics
"I am looking forward to meeting other TPD enthusiasts. By working together, we can progress novel modalities against devastating neurological disorders."
Associate Principal Scientist, Merck
“This meeting provides a wonderful opportunity for leaders in this field to share ideas.”
Harvard University
Download the Full Event Guide for more information on:
- 20+ Biotech & Pharma Speakers
- 4 Interactive Deep-Dive Workshops
- 6+ Hours of Networking
- & Much More!
